AdAlta (1AD) 2022年年度报告「ASX」.pdf

1、ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2022ADALTA LTDABN 92 120 332 925CORPORATE DIRECTORY 3CHAIRS LETTER 5CEO AND MANAGING DIRECTORS LETTER 6DIRECTORS REPORT 7AUDITORS INDEPENDENCE DECLARATION 29STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 30STATEMENT OF FINANCIAL POSITION 31STATEMEN

2、T OF CHANGES IN EQUITY 32STATEMENT OF CASH FLOWS 33NOTES TO THE FINANCIAL STATEMENTS 34DIRECTORS DECLARATION 50INDEPENDENT AUDITORS REPORT TO THE MEMBERS OF ADALTA LIMITED 51SHAREHOLDER INFORMATION 55CONTENTS AdAlta Limited Annual Report 2022 ABN 92 120 332 9252DIRECTORSDr Paul MacLemanDr Timothy Ol

3、dhamMs Elizabeth McCallDr Robert PeachDr David Fuller Dr James Williams(alternate to Elizabeth McCall)COMPANY SECRETARYMr Cameron JonesREGISTERED OFFICEUnit 15/2 Park DriveBundoora Vic 3083AUDITORDry Kirkness(Audit)Pty LtdGround Floor,50 Colin StreetWest Perth,Western Australia 6005On 1 July 2022 Bu

4、tler Settineri changed its name to Dry Kirkness.SHARE REGISTRYAutomic Registry ServicesLevel 5126 Phillip StreetSydney,NSW 2000Tel:1300 288 664STOCK EXCHANGE LISTINGAdalta Limited shares are listed on the Australian Securities Exchange.ASX CODE1ADWEBSITE.auCORPORATE DIRECTORYAdAlta Limited Annual Re

5、port 2022 ABN 92 120 332 9253AdAlta Limited Annual Report 2022 ABN 92 120 332 9254Dear fellow shareholders,Through FY2022 we continued to progress and expand our pipeline of i-body enabled assets.Following successful completion of the Phase I clinical trial for our lead asset,AD-214,in healthy volun

6、teers in July 2021,we have been maximising options available to us for the further development and partnering of this asset,ahead of drug product being available for clinical trials in patients.We have made significant progress towards a more convenient cost-effective inhaled formulation of AD-214 f